Published in Clin Endocrinol (Oxf) on June 01, 2002
Thyroid dysfunction from antineoplastic agents. J Natl Cancer Inst (2011) 1.86
Interferon alpha treatment and thyroid dysfunction. Endocrinol Metab Clin North Am (2007) 1.63
KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol (2016) 1.15
Hepatitis C and interferon induced thyroiditis. J Autoimmun (2010) 1.08
Breaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity. Endocr Rev (2013) 1.05
Interferon induced thyroiditis. Best Pract Res Clin Endocrinol Metab (2009) 1.04
KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol (2014) 0.99
Autoantibodies in chronic hepatitis C: A clinical perspective. World J Hepatol (2015) 0.96
The spectrum of thyroid dysfunction in an Australian hepatitis C population treated with combination Interferon-alpha2beta and Ribavirin. BMC Endocr Disord (2005) 0.91
Opportunistic autoimmune disorders: from immunotherapy to immune dysregulation. Ann N Y Acad Sci (2010) 0.86
Frequency of thyroid dysfunctions during interferon alpha treatment of single and combination therapy in hepatitis C virus-infected patients: a systematic review based analysis. PLoS One (2013) 0.85
Autoimmune and neoplastic thyroid diseases associated with hepatitis C chronic infection. Int J Endocrinol (2014) 0.84
The Spectrum of Autoimmune Thyroid Disease in the Short to Medium Term Following Interferon-alpha Therapy for Chronic Hepatitis C. Int J Endocrinol (2009) 0.81
The swinging thyroid in hepatitis C infection and interferon therapy. BMJ Case Rep (2009) 0.80
Association of interferon-alpha and ribavirin-induced thyroid dysfunction with severity of disease and response to treatment in pakistani asian patients of chronic hepatitis C. Hepat Res Treat (2012) 0.79
Autoimmune thyroid disorders in hepatitis C virus infection: Effect of interferon therapy. Indian J Endocrinol Metab (2013) 0.78
Interferon-alpha induced and ribavirin induced thyroid dysfunction in patients with chronic hepatitis C. Hepat Mon (2010) 0.78
Thyroid hormonal disturbances related to treatment of hepatitis C with interferon-alpha and ribavirin. Clinics (Sao Paulo) (2011) 0.75
Graves' Disease following Interferon Therapy for Chronic Hepatitis C Infection. Sultan Qaboos Univ Med J (2008) 0.75
Concurrent autoimmune hepatitis and grave's disease in hepatitis C during pegylated interferon α-2a and ribavirin therapy. Saudi J Gastroenterol (2011) 0.75
Interaction of interferon alpha therapy with thyroid function tests in the management of hepatitis C: a case report. J Med Case Rep (2016) 0.75
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet (2009) 13.03
The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology (2007) 6.68
NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology (2002) 4.44
Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology (2003) 4.10
Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology (2004) 3.93
The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology (2013) 3.14
Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem (2005) 2.99
Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes. Eur Heart J (2006) 2.93
The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology (2011) 2.86
Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology (2008) 2.70
Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology (2009) 2.66
Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology (2010) 2.56
Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response. Hepatology (2002) 2.51
Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. Hepatology (2012) 2.42
Treatment responses in Asians and Caucasians with chronic hepatitis C infection. World J Gastroenterol (2008) 2.39
Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology (2007) 2.36
Animal models of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol (2010) 2.32
Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection. J Hepatol (2012) 2.31
Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology (2003) 2.28
Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology (2006) 2.26
Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol (2011) 2.24
Serum 25-hydroxyvitamin D and glycated haemoglobin levels in women with gestational diabetes mellitus. Med J Aust (2011) 2.20
Feasibility of conducting a randomized control trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed? Hepatology (2011) 2.05
Noninvasive assessment of hepatic lipid composition: Advancing understanding and management of fatty liver disorders. Hepatology (2008) 2.03
Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology (2009) 2.02
Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. Hepatology (2009) 1.91
Mechanistic insights into the therapeutic use of high-dose allopurinol in angina pectoris. J Am Coll Cardiol (2011) 1.88
Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology (2013) 1.88
The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis (2007) 1.87
Role of naturally occurring CD4+ CD25+ regulatory T cells in experimental atherosclerosis. Arterioscler Thromb Vasc Biol (2007) 1.79
Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection. Hepatology (2013) 1.77
Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C. Hepatology (2014) 1.73
Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. J Clin Oncol (2009) 1.70
Hypoxia controls CD4+CD25+ regulatory T-cell homeostasis via hypoxia-inducible factor-1alpha. Eur J Immunol (2008) 1.69
NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. Gastroenterology (2005) 1.67
Subcutaneous emphysema in cavitary pulmonary tuberculosis without pneumothorax or pneumomediastinum. Lung India (2012) 1.67
Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology (2002) 1.66
Effect of a lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factors. J Gastroenterol Hepatol (2008) 1.64
Predictive value of high sensitivity CRP in patients with diastolic heart failure. Int J Cardiol (2007) 1.63
Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening. J Hepatol (2009) 1.61
Chromium supplementation does not improve glucose tolerance, insulin sensitivity, or lipid profile: a randomized, placebo-controlled, double-blind trial of supplementation in subjects with impaired glucose tolerance. Diabetes Care (2005) 1.60
Hepatic fat loss in advanced nonalcoholic steatohepatitis: are alterations in serum adiponectin the cause? Hepatology (2013) 1.57
Erythropoietin improves myocardial performance in doxorubicin-induced cardiomyopathy. Eur Heart J (2006) 1.52
Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol (2012) 1.52
C-reactive protein levels following acute myocardial infarction: effect of insulin infusion and tight glycemic control. Diabetes Care (2004) 1.51
The impact of renin-angiotensin-aldosterone system blockade on heart failure outcomes and mortality in patients identified to have aortic regurgitation: a large population cohort study. J Am Coll Cardiol (2011) 1.51
Kupffer cells mediate leptin-induced liver fibrosis. Gastroenterology (2009) 1.48
Islet-1 gene delivery improves myocardial performance after experimental infarction. Atherosclerosis (2012) 1.43
Preventing primary liver cancer: how well are we faring towards a national hepatitis B strategy? Med J Aust (2008) 1.42
Sociodemographic correlates of the increasing trend in prevalence of gestational diabetes mellitus in a large population of women between 1995 and 2005. Diabetes Care (2008) 1.41
Renin-angiotensin system blockers are associated with reduced mortality and heart failure hospitalization in patients paced for complete atrioventricular block. Heart Rhythm (2011) 1.41
Autoantibodies to oxidized low-density lipoprotein in patients with aortic regurgitation: association with aortic diameter size. Cardiology (2014) 1.41
Gestational diabetes in Iran: incidence, risk factors and pregnancy outcomes. Diabetes Res Clin Pract (2005) 1.37
IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study. PLoS Med (2011) 1.36
Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin Liver Dis (2002) 1.32
Point: Universal screening for gestational diabetes mellitus. Diabetes Care (2009) 1.28
Postpartum physical activity and related psychosocial factors among women with recent gestational diabetes mellitus. Diabetes Care (2005) 1.27
Non-alcoholic steatohepatitis in the Asia-Pacific region: future shock? J Gastroenterol Hepatol (2004) 1.24
Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology (2004) 1.24
HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology (2002) 1.23
Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol (2007) 1.23
Fitness versus fatness: moving beyond weight loss in nonalcoholic fatty liver disease. Hepatology (2010) 1.22
Thrombocytopenia due to rifampicin. Lung India (2012) 1.21
Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. J Gastroenterol Hepatol (2002) 1.21
Pathogenesis of NASH: animal models. Clin Liver Dis (2007) 1.20
Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome Med (2011) 1.19
IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice. J Gastroenterol (2010) 1.18
Gender differences in healthy ranges for serum alanine aminotransferase levels in adolescence. PLoS One (2011) 1.17
The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis. J Am Coll Cardiol (2005) 1.17
High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease. J Am Coll Cardiol (2013) 1.16
Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. Hepatology (2008) 1.15
The Australasian Diabetes in Pregnancy Society consensus guidelines for the management of type 1 and type 2 diabetes in relation to pregnancy. Med J Aust (2005) 1.14
Oral tolerance with heat shock protein 65 attenuates Mycobacterium tuberculosis-induced and high-fat-diet-driven atherosclerotic lesions. J Am Coll Cardiol (2002) 1.12
Circulating endothelial progenitor cells in patients with cardiac syndrome X. Heart (2006) 1.11
Deficiency of antigen-presenting cell invariant chain reduces atherosclerosis in mice. Circulation (2010) 1.11
The role of HbA1c in the diagnosis of diabetes mellitus in Australia. Med J Aust (2012) 1.10
Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. Gastroenterology (2012) 1.09
Effect of anti-TNFalpha treatment on circulating endothelial progenitor cells (EPCs) in rheumatoid arthritis. Life Sci (2006) 1.09
Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance. Gastroenterology (2009) 1.09
Modelling the hepatitis C virus epidemic in Australia. Drug Alcohol Depend (2007) 1.08
Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis. Hepatology (2006) 1.08
The role of thiazolidinediones in non-alcoholic steatohepatitis - a systematic review and meta analysis. J Hepatol (2011) 1.07
A case of Goodpasture's syndrome complicating pregnancy with dialysis requiring renal failure responding to plasmapheresis and termination of pregnancy. Ren Fail (2013) 1.06
Management of nonalcoholic steatohepatitis: an evidence-based approach. Clin Liver Dis (2012) 1.05
Cell and molecular regulation of endothelin-1 production during hepatic wound healing. Mol Biol Cell (2003) 1.05
Mother to child transmission of diabetes mellitus: does gestational diabetes program Type 2 diabetes in the next generation? Diabet Med (2006) 1.03
Comparison of hemoglobin A1c with fasting plasma glucose and 2-h postchallenge glucose for risk stratification among women with recent gestational diabetes mellitus. Diabetes Care (2011) 1.03
Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease. J Gastroenterol Hepatol (2011) 1.01
Are either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisal. Arthritis Rheum (2012) 1.00
Exercise and the liver: implications for therapy in fatty liver disorders. Semin Liver Dis (2012) 0.99
Allopurinol treatment reduces arterial wave reflection in stroke survivors. Cardiovasc Ther (2008) 0.99
Circulating endothelial progenitor cells and clinical outcome in patients with congestive heart failure. Heart (2007) 0.99
Recent findings on natural products with erectile-dysfunction activity. Phytochemistry (2003) 0.99
Visceral adiposity in gastrointestinal and hepatic carcinogenesis. Cancer Lett (2012) 0.99
Hepatitis C virus induces the cannabinoid receptor 1. PLoS One (2010) 0.98
Molecular mechanisms of insulin resistance in chronic hepatitis C. World J Gastroenterol (2009) 0.98
Pro-oxidant-mediated hepatic fibrosis and effects of antioxidant intervention in murine dietary steatohepatitis. Int J Mol Med (2009) 0.98
Circulating apoptotic progenitor cells in patients with congestive heart failure. PLoS One (2008) 0.97